What happened with PFSA today?
No read yet
Uses news and trading volume to explain the day’s move and how it relates to the market.
Stop guessing. Get the call, a three-month target price, the best and worst cases, and a source for every claim.
Profusa’s first product, Lumee Oxygen, helps clinicians measure blood flow to tissue during and after procedures to restore circulation in patients with severely reduced blood flow to their limbs. A tiny sensor injected into tissue sends a light signal to an external reader. Lumee Oxygen has launched in Europe, but commercial activity remains limited; Profusa plans to sell directly to healthcare facilities and expects it to supply nearly all commercial revenue until other products receive approval.
Profusa is also developing Lumee Glucose to provide continuous glucose readings for people with diabetes or prediabetes. It remains in clinical trials. Planned sales to hospitals and pharmacies depend on regulatory authorization. No Profusa product is approved for commercial sale in the United States, and European Lumee Oxygen sales depend on maintaining its CE mark and meeting European medical-device rules.
Profusa has also received research funding from NIH and DARPA, which reimburse eligible costs or pay for approved research milestones. Operations have been funded mainly through equity and debt, and further funding is needed to develop products and build commercial sales.
The risk section is the longest, dullest part of the filing. This keeps only what can really hurt you: where it hits, how hard, when it plays out.
Every company claims an edge. Each one is checked against hard numbers like margins and returns: which hold, and which line gives way first.
Profusa’s prospects hinge on biosensor approval and adoption; Siemens Healthineers and Perimed are oxygen-monitoring competitors to watch that are missing from this list.
Abbott Laboratories already sells Libre continuous glucose monitors in the diabetes-monitoring market Profusa hopes to enter with Lumee Glucose, which remains in clinical trials. Watch advances or approvals for Libre: they could reduce demand for Profusa’s product if it wins authorization to sell to hospitals and pharmacies.
Medtronic sells continuous glucose monitors for diabetes care, competing with the market Profusa is pursuing with its still-investigational Lumee Glucose. Watch improvements to Medtronic’s Guardian Connect and its diabetes products prescribed by endocrinologists and primary care physicians: competing technology could make it harder for Profusa to attract users once approved.
Abbott Laboratories earningsABT
Abbott’s report will show how demand for its Libre glucose monitors is changing, indicating how much competition Profusa may face if Lumee Glucose reaches the market.
Look at Abbott’s diabetes business and any reported progress or wider use of Libre. Stronger demand or product advances would show Abbott reinforcing its established position, making it harder for Profusa to win hospitals, pharmacies and users if Lumee Glucose is authorized. Weaker demand without clear product advances would point to less pressure, but would not show that customers will choose Profusa.
